This site is intended for health professionals only

Meningitis B vaccine ‘effective as part of child vaccine schedule’

A meningitis B vaccine could be added to the routine schedule for infant vaccines without affecting its immunogenicity, finds a large European study.

The randomised controlled trial – funded by Novartis - found that the multicomponent ‘4CMenB' vaccine was effective when given as part of the routine childhood vaccination schedule and shows minimal interference with the routine vaccines.

After three vaccinations, 99% of infants developed immunity - defined by researchers as a human complement serum bactericidal activity titre of 1.5 or greater – against two strains of meningitis B.

In children who were vaccinated at two, four and six months, alongside their routine vaccinations, 79% developed immunity. Of those who received the vaccine at two, four and six months, and had their routine vaccinations separately, 86% developed immunity. And of those who had the vaccination at two, three and four months alongside their routine vaccinations, 82% developed immunity.

Study author Professor Andrew Pollard, professor of paediatric infection and immunity at the University of Oxford, said: ‘The flexibility in schedule allows [4CMenB vaccine] to be incorporated into a range of country-specific immunisation schedules and for primary immunisation to be completed in early infancy.'

JAMA, February 8, 2010


Visit Pulse Reference for details on 140 symptoms, including easily searchable symptoms and categories, offering you a free platform to check symptoms and receive potential diagnoses during consultations.